CKD as an independent driver of polypharmacy
Clinical Kidney Journal · 01.07.2026 · 19 (7)
DOI: 10.1093/ckj/sfag184 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Kidney Journal, online erschienen am 03.06.2026. Verfasst von Rafael Santamaria und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Service, Reina Sofia University Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cor…. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Themen: Medikationssicherheit
Abstract (Originalsprache)
A clinically important yet underexplored question is whether chronic kidney disease ( CKD) contributes to medication burden beyond the effect attributable to chronological age alone. In this retrospective observational study of 70 385 adults, medication burden increased with age, worsening kidney function and higher albuminuria. Strikingly, younger adults with impaired kidney function displayed medication profiles comparable to those of older adults with preserved kidney function. This finding is consistent with a shift in polypharmacy patterns and premature pharmacological ageing. Therefore, CKD should therefore be recognized as an age-independent driver of treatment complexity, calling for stage-and age-adapted medication stew-ardship. CKD is a major global health challenge that requires complex medical management, often involving multiple medications [ 1 , 2 ]. Polypharmacy, defined as the concurrent use of ≥ 5 drugs is highly prevalent in CKD, especially in advanced stages
Autor:innen und Institutionen
- Nephrology Service, Reina Sofia University Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain.
- Cardiology Service, University Hospital La Paz, Madrid, Spain.
- Atrys Health, Madrid, Spain.
- BioPharmaceuticals Medical, AstraZeneca, Madrid, Spain.
- Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
- Nephrology Service, University Hospital Infanta Leonor, Madrid, Spain.
ORCID-Profile: Rafael Santamaria, Carlos Escobar, Roberto Alcázar
Förderung
- AstraZeneca
Zitieren
APA
Santamaria, R., Escobar, C., Hernández, I., Palacios, B., Aranda, U., & Alcázar, R. (2026). CKD as an independent driver of polypharmacy. Clinical Kidney Journal, 19(7). https://doi.org/10.1093/ckj/sfag184
Vancouver
Santamaria R, Escobar C, Hernández I, Palacios B, Aranda U, Alcázar R. CKD as an independent driver of polypharmacy. Clinical Kidney Journal. 2026;19(7). doi:10.1093/ckj/sfag184
BibTeX
@article{Santamaria2026,
author = {Santamaria, Rafael and Escobar, Carlos and Hernández, Ignacio and Palacios, Beatriz and Aranda, Unai and Alcázar, Roberto},
title = {CKD as an independent driver of polypharmacy},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {7},
doi = {10.1093/ckj/sfag184}
}
EUVIMED